Publication: Effect of Bardoxolone Methyl on the Urine Albumin-To-Creatinine Ratio in Patients With Type 2 Diabetes and Stage 4 Chronic Kidney Disease

In patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl, changes in albuminuria were directly related to changes in eGFR.

  • Relative to placebo, bardoxolone methyl treatment resulted in a significant decrease in albuminuria when indexed to eGFR.
  • Mean increases in eGFR from baseline at both week 48 and 4 weeks off treatment were not different in the highest and lowest quartiles of patients stratified by week 12 UACR changes.